Maximus (NYSE:MMS – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
Maximus Stock Down 0.5 %
Maximus stock traded down $0.39 during mid-day trading on Thursday, hitting $72.50. 1,701,725 shares of the company’s stock were exchanged, compared to its average volume of 408,183. The stock has a market cap of $4.37 billion, a P/E ratio of 14.50 and a beta of 0.77. The stock has a 50 day moving average of $87.17 and a two-hundred day moving average of $87.75. Maximus has a 1-year low of $71.75 and a 1-year high of $93.97. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.59.
Insider Buying and Selling
In related news, insider Michelle F. Link sold 1,363 shares of Maximus stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $92.56, for a total transaction of $126,159.28. Following the sale, the insider now directly owns 6,567 shares of the company’s stock, valued at $607,841.52. This trade represents a 17.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.40% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Maximus Company Profile
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Articles
- Five stocks we like better than Maximus
- What Are Dividend Contenders? Investing in Dividend Contenders
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Stock Analyst Ratings and Canadian Analyst Ratings
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.